Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs

Xingshun Qi; Valerio De Stefano; Xiaozhong Guo; Daiming Fan

doi:10.1160/TH14-10-0892

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2015; 113(06): 1378-1380
DOI: 10.1160/TH14-10-0892

Letters to the Editor

Schattauer GmbH

Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in liver diseases: Meta-analysis of RCTs

Authors

Xingshun Qi^*

¹Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China

²Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China
Valerio De Stefano^*

³Institute of Hematology, Catholic University, Rome, Italy
Xiaozhong Guo

¹Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang, China
Daiming Fan

²Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China

Abstract

Full Text

References

References
1 McHutchison JG. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357: 2227-2236.
2 Afdhal NH. et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 2012; 367: 716-724.
3 Dultz G. et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011; 55: 229-232.
4 Kawano N. et al. Portal vein thrombosis during eltrombopag treatment for immune thrombocytopenic purpura in a patient with liver cirrhosis due to hepatitis C viral infection. J Clin Exp Hematop 2013; 53: 151-155.
5 Terrault NA. et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol 2014; 61: 1253-1259.
6 Afdhal NH. et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146: 442-452 e1.
7 Zocco MA. et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 2009; 51: 682-689.
8 Saleh MN. et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121: 537-545.
9 Qi X, Han G, Fan D. Management of portal vein thrombosis in liver cirrhosis. Nat Rev Gastroenterol Hepatol 2014; 11: 435-446.
10 Qi X. et al. Occlusive portal vein thrombosis as a new marker of decompensated cirrhosis. Med Hypotheses 2011; 76: 522-526.
11 Dentali F. et al. Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 2008; 99: 675-682.
12 Qi X. et al. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12: 1801-1812 e7.

Supplementary Material

Online Supplementary Material (PDF) (PDF)